Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
Electrophysiology Program, Heart and Vascular Institute, Penn State University College of Medicine, 500 University Drive, Room H1511, P. O. Box 850, MC H047, Hershey, PA 17033, USA. gnaccarelli@hmc.psu.edu
Gerald V
GV
Naccarelli
Mario D
MD
Gonzalez
D000925:Anticoagulants / Q000008:administration & dosage*; D000991:Antithrombins / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000601:surgery*; D001562:Benzimidazoles / Q000008:administration & dosage*; D017115:Catheter Ablation / Q000379:methods*; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage*; D012307:Risk Factors; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage*; D013923:Thromboembolism / Q000517:prevention & control*; D014481:United States; D014859:Warfarin / Q000008:administration & dosage*; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran